Physician profile
Alyssa Morrish
NPI 1205473535
$1,370.80
in general payments reported to CMS, 2019-2025
22 companies · $468 in 2025
The $468 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $37.94 · 2023: $443 · 2024: $422 · 2025: $468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,333.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,332.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $280.81 | 2023-2025 | Imfinzi, Imjudo, Andexxa |
| Abbvie INC. | $209.64 | 2023-2025 | |
| Ethicon US, LLC | $192.23 | 2023-2025 | Surgicel Nu-Knit, Vistaseal, Neuwave |
| Becton, Dickinson and Company | $68.73 | 2025 | Arista |
| Takeda Pharmaceuticals U.S.A., INC. | $67.68 | 2023 | Gattex |
| Vivus LLC | $62.32 | 2023-2025 | Qsymia, Pancreaze |
| Nestle Healthcare Nutrition INC. | $52.29 | 2023 | |
| Tela Bio, INC. | $49.14 | 2024 | Ovitex 2s |
| Tersera Therapeutics LLC | $46.86 | 2024-2025 | Xermelo |
| Davol INC. | $39.59 | 2025 | Phasix Mesh |
| Cardiovascular Systems INC. | $37.94 | 2021 | |
| Aimmune Therapeutics, INC. | $36.63 | 2024-2025 | Zenpep |
| Alcresta Therapeutics, INC. | $34.41 | 2023 | Relizorb |
| Tempus Ai, INC | $28.46 | 2024 | |
| Fresenius Kabi USA, LLC | $24.23 | 2023 | Smoflipid |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sirtex Medical INC | $23.62 | 2023 | Sir-Spheres Microspheres |
| Kerecis Limited | $23.57 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Merck Sharp & Dohme LLC | $22.81 | 2024 | Zerbaxa, Dificid, Prevymis |
| Baxter Healthcare | $19.63 | 2023 | Perclot |
| Heron Therapeutics, INC. | $18.16 | 2023 | Zynrelef |
| Integra Lifesciences Corporation | $18.12 | 2024 | Codman Certas, Duraseal Exact Spinal Sealant System, Codman Hakim |
| Medtronic, INC. | $13.93 | 2023 | Emprint |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alyssa Morrish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.